The MPM market is growing due to rising asbestos exposure, better diagnostic methods, and progress in targeted therapies. Key companies, including Bristol-Myers Squibb, Merck, and ImmunoGen, are advancing treatments such as immunotherapies and combination approaches. These innovations aim to improve patient outcomes and meet the significant unmet medical needs in malignant pleural mesothelioma management.

Access Market Report: https://shorturl.at/Yg2cZ